Italia markets closed

Dow Jones
38.773,38
+184,22(+0,48%)
Nasdaq
17.903,16
+214,28(+1,21%)
Nikkei 225
38.102,44
-712,12(-1,83%)
EUR/USD
1,0740
+0,0031(+0,29%)
Bitcoin EUR
62.324,29
+319,67(+0,52%)
CMC Crypto 200
1.402,26
+14,10(+1,02%)

NBIX Mar 2025 170.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

7,90

0,00

(0,00%)

In data: 03:40PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat